Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 991

Sort by

Sort Order Select

Journal Articles

CEBPA bZip mutations: just a single shot

Jorge Sierra, Josep F. Nomdedeu

Blood (2021) 138 (13): 1091–1092.

https://doi.org/10.1182/blood.2021011263

Published: 2021

Journal Articles

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Huthayfa Mujahed, Sophia Miliara, Anne Neddermeyer, Sofia Bengtzén, Christer Nilsson, Stefan Deneberg, Lina Cordeddu, Karl Ekwall, Andreas Lennartsson, Sören Lehmann

Blood (2020) 136 (3): 339–352.

https://doi.org/10.1182/blood.2019002326

Published: 2020

Includes: Supplemental data

Journal Articles

Secondary leukemia in patients with germline transcription factor mutations ( RUNX1 , GATA2 , CEBPA )

Anna L. Brown, Christopher N. Hahn, Hamish S. Scott

Blood (2020) 136 (1): 24–35.

https://doi.org/10.1182/blood.2019000937

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia

Katherine Tarlock, Todd Alonzo, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Tiffany Hylkema, Jenny L. Smith, Julia E. Maxson, Soheil Meshinchi

Blood (2020) 135 (18): 1603–1606.

https://doi.org/10.1182/blood.2019004179

Published: 2020

Includes: Supplemental data

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Does Venetoclax Cause Vitiligo?

Sujatha Baddam, MD, Jorge Diaz Castro, MD

Blood (2019) 134 (Supplement_1): 5139.

https://doi.org/10.1182/blood-2019-130854

Published: 2019

Journal Articles

Modified Conut Score Can Predict Prognosis in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Hajime Senjo, MD, Masahiro Onozawa, Daisuke Hidaka, Shota Yokoyama, Satoshi Yamamoto, MD PhD, Yutaka Tsutsumi, Yoshihito Haseyama, Takahiro Nagashima, Akio Mori, Shuichi Ota, Hajime Sakai, Toshimichi Ishihara, Takuto Miyagishima, Yasutaka Kakinoki, Mitsutoshi Kurosawa, Hajime Kobayashi, Hiroshi Iwasaki, Takeshi Kondo, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 3854.

https://doi.org/10.1182/blood-2019-122804

Published: 2019

Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Blood (2019) 134 (Supplement_1): 2691.

https://doi.org/10.1182/blood-2019-124529

Published: 2019

Journal Articles

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Kellie J Archer, PhD, Allison Walker, Krzysztof Mrózek, MD PhD, Andrew J. Carroll, PhD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Marius Bill, MD PhD, Christopher J. Walker, PhD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2694.

https://doi.org/10.1182/blood-2019-125727

Published: 2019

Journal Articles

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Anna L Brown, PhD, Milena Babic, BMPharBio (Hons), Andreas Schreiber, Jinghua Feng, PhD, Julia Dobbins, BSc (Hons), Peer Arts, PhD, Paul Wang, PhD, Kerry Phillips, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Parvathy Venugopal, PhD MSc, BSc, Susan Branford, PhD FFSc (RCPA), Nicola Poplawski, MD, Christopher N Hahn, PhD, Hamish S Scott, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3794.

https://doi.org/10.1182/blood-2019-131642

Published: 2019

Journal Articles

Strategy for Identification of an Inherited Leukemia Predisposition in a 299 Patients Cohort with Tumor-Only Sequencing Data

Almudena Aguilera Díaz, MSc, BS, Sara Palomino-Echeverria, MSc, BSc, Iria Vazquez, PhD BSc, Beñat Ariceta, BSc, Maria Jose Larrayoz, BSc, Amagoia Mañu, BSc, Zuriñe Blasco-Iturri, MSc, BSc, Matxalen Olivares Salaverri, MD, Maria Teresa Olave Rubio, MD, Teresa Bernal Del Castillo, MD PhD, Jose J. Rifon Roca, MD, Ana Alfonso Pierola, MD PhD, Felipe Prosper, MD PhD, Marta Fernández-Mercado, PhD MSc, BSc, Maria Jose Calasanz, PhD BSc

Blood (2019) 134 (Supplement_1): 1415.

https://doi.org/10.1182/blood-2019-126634

Published: 2019

Journal Articles

Mutational Landscape of Pediatric Acute Myeloid Leukemia: A Report of the AML-BFM Study Group with a Targeted NGS Approach in 525 Patients Integrating De Novo, Relapsed and Secondary AML

Christiane Walter, MSc, Markus Schneider, PhD, Nils Von Neuhoff, PhD, Helmut Hanenberg, MD, Dirk Reinhardt, MD, Mareike Rasche, MD

Blood (2019) 134 (Supplement_1): 1398.

https://doi.org/10.1182/blood-2019-129778

Published: 2019

Journal Articles

Detection of Measurable Residual Disease May Better Predict the Outcome Rather Than Mutations Based on Next-Generation Sequencing in Acute Myeloid Leukemia with Biallelic Mutations of CEBPA

Jing Wang, MD, Hao Jiang, Xiaojun Huang, MD, Guorui Ruan, Run-Qing Lu

Blood (2019) 134 (Supplement_1): 1449.

https://doi.org/10.1182/blood-2019-127696

Published: 2019

Journal Articles

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Blood (2019) 134 (Supplement_1): 1421.

https://doi.org/10.1182/blood-2019-127937

Published: 2019

Journal Articles

Deciphering Common Gene Fusions and Mutations in Acute Leukemia of Ambiguous Lineage

Panxiang Cao, Mingyu Wang, MD, Fang Wang, MD, Yang Zhang, MD, Xue Chen, MD, Xiaoli Ma, Yu Zhang, Hongxing Liu, MD

Blood (2019) 134 (Supplement_1): 3793.

https://doi.org/10.1182/blood-2019-130628

Published: 2019

Journal Articles

Leukemic Stem Cell Phenotype Is Associated with Mutational Profile in Acute Myeloid Leukemia

Ja Min Byun, MD, Dong-Yeop Shin, MD PhD, Youngil Koh, Sung-Soo Yoon, MD PhD, Junshik Hong, MD, Inho Kim, MD PhD

Blood (2019) 134 (Supplement_1): 3852.

https://doi.org/10.1182/blood-2019-126373

Published: 2019

Journal Articles

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Xiaohong Liu, Wenbing Duan, Jing Wang, MD, Jinsong Jia, Lizhong Gong, Shen-ye Lu, MD, Xiaosu Zhao, PhD, Ying-Jun Chang, Yue-Yun Lai, Hongxia Shi, Yu Wang, Chenhua Yan, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 3823.

https://doi.org/10.1182/blood-2019-128505

Published: 2019

Journal Articles

Untangling the Transcriptional Mis-Regulation Driven By Pml;rara

William Villiers, MSc, Paul Lavender, PhD, Audrey Kelly, PhD, Michael Lim, MD PhD, Cameron Osborne, PhD, Richard Dillon, MA, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 282.

https://doi.org/10.1182/blood-2019-125555

Published: 2019

Journal Articles

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Bhavuk Garg, PhD, Hrishikesh M Mehta, PhD, Ralph Kamel, Marshall S. Horwitz, MD PhD, Seth J. Corey, MD

Blood (2019) 134 (Supplement_1): 103.

https://doi.org/10.1182/blood-2019-127409

Published: 2019

Journal Articles

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Blood (2019) 134 (Supplement_1): 289.

https://doi.org/10.1182/blood-2019-128682

Published: 2019

NARROW

CEBPA bZip mutations: just a single shot

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Secondary leukemia in patients with germline transcription factor mutations ( RUNX1 , GATA2 , CEBPA )

Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Does Venetoclax Cause Vitiligo?

Modified Conut Score Can Predict Prognosis in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Strategy for Identification of an Inherited Leukemia Predisposition in a 299 Patients Cohort with Tumor-Only Sequencing Data

Mutational Landscape of Pediatric Acute Myeloid Leukemia: A Report of the AML-BFM Study Group with a Targeted NGS Approach in 525 Patients Integrating De Novo, Relapsed and Secondary AML

Detection of Measurable Residual Disease May Better Predict the Outcome Rather Than Mutations Based on Next-Generation Sequencing in Acute Myeloid Leukemia with Biallelic Mutations of CEBPA

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Deciphering Common Gene Fusions and Mutations in Acute Leukemia of Ambiguous Lineage

Leukemic Stem Cell Phenotype Is Associated with Mutational Profile in Acute Myeloid Leukemia

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Untangling the Transcriptional Mis-Regulation Driven By Pml;rara

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only